Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Galectin Therapeutics Inc (GALT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.98-13.98%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for GALT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improvement in earnings trajectory | A primary condition in Galectin Therapeutics Inc's published investment case. The stated target is EPS loss narrows from -0.37 in 2026 to less negative or break-even by end 2027. | Broken | EPS loss worsens beyond -0.37 in FY26 and FY27 | Diluted EPS: $-0.14 per share FY2026-Q2; GAAP. Published target: EPS loss narrows from -0.37 in 2026 to less negative or break-even by end 2027. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 2026-0.14 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making clinical-stage biotechnology business, not an established earnings compounder. The long-term thesis is in a watch state: management is on track with the trial plan, but recent financial performance has lagged its industry cohort and the evidence snapshot has low confidence.
The evidence provides no valuation measure or direct account of market expectations, so it is not possible to judge whether GALT is cheap, fair, or expensive versus peers. Expectations appear sensitive to execution: another guidance cut could lead analysts to lower estimates, while the recent earnings misses and equity issuance are important context.
Near term, earnings reliability is a concern, with consecutive misses and a high stated risk of another miss. Over the multi-year view, management has reached agreement with the FDA on key Phase 3 trial elements and is preparing the protocol, while debt conversion strengthened the balance sheet; cash declined slightly in the latest reported quarter, and management says available funding supports operations and research through mid-2027.
The main company-specific hinge is whether belapectin’s Phase 3 trial advances along the stated regulatory path and whether funding remains sufficient. Near term, guidance and earnings execution matter; weakening employment data could weigh on cyclical and healthcare names, while continued strong results and guidance from sector peers could support broader healthcare sentiment.
Over the next 1 to 3 years, GALT’s long-term thesis depends on clinical execution and financial discipline, but recent misses and high risk leave the evidence cautious. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Sufficient funding and credit agreements | A supporting condition in Galectin Therapeutics Inc's published investment case. The stated target is Maintain credit lines and liquidity through 2026. | Intact | Loss of credit agreements or liquidity crisis | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
FDA trial progress and approvals | Galectin Therapeutics has FDA trial agreement that boosts confidence in its drug development. | Intact | FDA trial agreement is withdrawn or major trial setbacks occur | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.33 → $-0.23 · observed estimates
$0.39B → $0.39B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-07-25 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-07-26 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-07-27 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-07-28 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-07-29 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-07-30 | $-0.33 | $0 | 1 / 1 |
| 2026-07-31 | $-0.33 | $0 | 1 / 1 |
| 2026-08-01 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-08-02 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-08-03 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-08-04 | $-0.33 | $0 | 1 / 1 |
| 2026-08-05 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-08-06 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-08-07 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-08-08 | $-0.33 | $0 | 1 / 1 |
| 2026-08-09 | $-0.33 | $0 | 1 / 1 |
| 2026-08-10 | $-0.33 | $0 | 1 / 1 |
| 2026-08-12 | $-0.33 | $0 | 1 / 1 |
| 2026-08-13 | $-0.33 | $0 | 1 / 1 |
| 2026-08-14 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-08-15 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-08-16 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-08-17 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-08-18 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-08-19 | $-0.33 | $385,244,000 | 1 / 1 |
| 2026-08-20 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-08-21 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-08-22 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-08-23 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-08-24 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-08-25 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-08-26 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-08-27 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-08-28 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-08-29 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-08-30 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-08-31 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-01 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-02 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-03 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-04 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-05 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-06 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-07 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-08 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-09 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-10 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-11 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-12 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-13 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-14 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-15 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-16 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-17 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-18 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-19 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-20 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-21 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-22 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-23 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-24 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-25 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-26 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-27 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-28 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-29 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-09-30 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-01 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-02 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-03 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-04 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-05 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-06 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-07 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-08 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-09 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-10 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-11 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-12 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-13 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-14 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-15 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-16 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-17 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-18 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-19 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-20 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-21 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-22 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-23 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-24 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-25 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-26 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-27 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-28 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-29 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-30 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-10-31 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-11-01 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-11-02 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-11-03 | $-0.23 | $385,244,000 | 1 / 1 |
| 2026-11-04 | $-0.23 | $385,244,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.